Please assess the completion status of the following clinical trial:

Trial Title: Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is an adult more than or equal 18 years old at the time of informed consent.~* Patient has pathologic diagnosis of solid tumor (breast cancer, colorectal, lung, sarcoma, head and neck, sarcoma, genitourinary or gynecological cancer).~* Patients who started chemotherapy (with or without radiotherapy) or planned to receive chemotherapy for at least 12 weeks.~* Patient has an Eastern Cooperative Oncology Group performance status between 0 and 2.~* Patient with Hb ≤11 g/dL.~* Patient has a Life expectancy at least 6 months.~* Adequate hepatic and renal function defined as a serum aspartate aminotransferase or alanine aminotransferase level that are no more than 3 times the upper limit of the normal range, a serum bilirubin level that is no more than 2 times the upper limit of the normal range and a serum Creatinine level of less than 2 mg per deciliter.~* Patient is able to understand and provide informed consent to participate in the study.~Exclusion Criteria:~* Patient has Hb \< 8.0 g/dL~* Patient presenting with hematologic malignancy including~* Prior gastric surgery.~* Patients on definitive radiotherapy alone.~* Patients with relevant history (within six weeks) or clinical evidence of hemolysis or active bleeding that could, in the investigator's judgment, be a potential cause for the anemia (no gross hematuria, hemoptysis, hematochezia or melena and negative stool for hemoccult)~* Presence of other nutritional anemia; deficiency of vitamin B12 less than 187 pg/ml and deficiency of Folate less than 3.1 ng/ml according to the local laboratory normal ranges~* Patient has Iron overload (Serum Ferritin more than 800 ng/ml or Transferrin saturation (TSAT) more than 40%)~* Patient is pregnant or lactating.~* Patient has a personal or family history of hemochromatosis.~* Patient has hypersensitivity to any form of IV iron.~* Patient has received red blood cells transfusion or used erythropoietin within 2 weeks of enrollment into the study.~* Patient has received any form of intravenous iron within the last 12 weeks~* Patient has received oral iron supplements within 1 month of enrollment to the study, except for multivitamin supplements containing less than 30 mg iron.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric carboxymaltose (ferrinject) (Type: EXPERIMENTAL): Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~* Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~* If the needed Ferric carboxymaltose dose is \> 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion

Based on this trial design, predict the completion outcome and termination type (if applicable).